Coenzyme Q-10 and cardiovascular health

Alternative Therapies in Health and Medicine

Volumn 10, Issue 1, 2004, Pages 22-31+90

  Jones, Kenneth ^a   Hughes, Kerry ^b   Mischley, Laurie ^c   McKenna, Dennis J ^d,e  

^a Armana Research Inc   (Canada)

^b Ethnopharm Consulting   (United States)

^c University Clinic   (United States)

^d Inst for Nat Products Research   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; DILTIAZEM; DOXORUBICIN; ENALAPRIL MALEATE; HYDROSOLUBLE Q GEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MENAQUINONE; METOPROLOL; MEVINOLIN; NITRATE; SIMVASTATIN; SQUALESTATIN; SUCCINATE DEHYDROGENASE; TRINITRATE; UBIDECARENONE; VITAMIN K GROUP; WARFARIN;

ABDOMINAL DISCOMFORT; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUING EDUCATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HEARTBURN; HUMAN; NAUSEA; REVIEW; STOMACH DISEASE; THROMBOCYTE AGGREGATION; VOMITING;

ANIMALS; CARDIOVASCULAR DISEASES; CORONARY CIRCULATION; DRUG INTERACTIONS; HUMANS; REGIONAL BLOOD FLOW; UBIQUINONE;

EID: 0348049537     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Folkers K, Langsjoen P, Langsjoen PH, Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Comm. 1992;182:247-253.
2. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA. 1985;82:4240-4244.
3. Karlsson J, Gunnes S, Semb B. Muscle fibers, ubiquinone and exercise capacity in effort angina. Mol Cell Biochem. 1996:179:179-184.
4. Crane FL, Hatefi Y, Lester RL, et al. Isolation of a quinone from beefheart mitochondria. Biochim Biophys Acta. 1957;25:220-221.
5. Ernster L, Dallner G. Biochemical physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195-204.
6. Walker UA, Byrne E. The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Acta Neurolog Scand. 1995;92:273-280.
7. Battino M, Ferri E, Gorini A, et al. (1990). Natural distribution and occurrence of coenzyme Qhomologues. Membrane Biochem. 1990;9:179-190.
8. Ravaglia G, Forti P, Maiolo F, et al. Effect of micronutrient status on natural killer cell immune function in healthy free-living subjects aged ≥ 90 y. Am J Clin Nutr. 2000;71:590-598.
9. Lenaz G, Gato R, Castelluccio C, et al. An updating of the biochemical function of coenzyme Qin mitochondria. Mol Aspects Med. 1994;15(suppl);s29-s36.
10. Mataix J, Manas M, Quiles J, et al. Coenzyme Q content depends upon oxidative stress and dietary fat unsaturation. Mol Aspects Med. 1997; 18(suppl):S129-S135.
11. Huertas JR, Battino M, Lenaz G, et al. Changes in mitochondrial and microsomal rat liver coenzyme Q9 and Q10 content induced by dietary fat and endogenous lipid peroxidation. FEBS Lett. 1991;287(1-2):89-92.
12. Yamashita S, Yamamoto Y. (1997). Simultaneous detection of ubiquinol and ubiquinone in human plasm a as a marker of oxidative stress. Anal Biochem. 1997;250:66-73.
13. Yamamoto Y, Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress, Mol Aspects Med. 1997;18(suppl):S79-S84.
14. Schnurr K, Hellwing M, Seidemann B, et al. Oxygenation of biomembranes by mammallan lipoxygenases: the tole of ubiquinone. Free Rad Biol Med. 1996;20:11-21.
15. Okamoto H, Kawaguchi H, Togashi H, et al. Effect of coenzyme Q10 on structural alterations in the renal membrane of stroke-prone spontaneously hypertensive rats. Biochem Med Metabol Biol. 1991;45:216-226.
16. Maulik N, Yoshida T, Engelman RM, et al. Dietary coenzyme Q10 supplement renders swine hearts resistant to ischemia-reperfusion injury, Am J Physiol Heart Circ Physiol. 2000;278:H1084-H1090.
17. Portakal O, Inal-Erden M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. Clin Biochem, 1999;32(6):461-466.
18. Serebruany VL, Herzog WR, Atamas SP, et al. Hemostatic changes after dietary coenzyme Q10 supplementation in swine. J Cardiovasc Pharmacol. 1996;28:175-181.
19. Witting PK, Pettersson K, Letters J, Stocker R. Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. Free Rad Biol Med. 2000;29(3-4):295-305.
20. Singh RB, Shinde SN, Chopra RK, et al. Effect of coenzyme Q10 on experimental atherosclerosis and chemical composition and quality of atheroma in rabbits. Atherosclerosis. 2000;148(2):275-282.
21. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analysis of clinical trials. Mol Aspects Med. 1997;18(suppl):S159-S168.
22. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 1999;33:1549-1552.
23. Singh RB, Niaz MA. Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. Int J Cardiol, 1999:68:23-29.
24. Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg. 1996;61:829-833.
25. Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J Cardiac Fail. 1995;1:101-107.
26. Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med. 1994; 15(suppl):S165-S175.
27. Langsjoen PH, Folkers K, Lyson K, et al. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr. 1988;66:583-590.
28. Chen YF, Lin YS, Wu SC. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J Thorac Cardiovasc Surg. 1994;107:242-247.
29. Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:1528-1533.
30. Judy WV, Hall JH, Toth PD, et al. Double blind cross over study of coenzyme Q10 in heart failure. In: Folkers K, Yamamura Y, eds, Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam, Holland: Elsevier; 1986:315-323.
31. Poggesi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy: a medium-term randomized double-blind study versus placebo. Curr Ther Res. 1991;49:878-886.
32. Serra G, Lissoni F, Piermonti C, et al. Evaluation of CoQ10 in patients with moderate heart failure and chronic stable effort angina. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and Clinical Aspecta of Coenzyme Q. 6. Amsterdam, Holland: Elsevier; 1991:327-338.
33. Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999;13:203-208.
34. Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-eontrolled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347-353.
35. Langsjoen P, Langsjoen P, Willis R, et al. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;15(suppl):265-272.
36. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001;94(11):1112-1117.
37. Serebruany VL, Ordonez JV, Herzog WR, et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol. 1997:29:16-22.
38. Kato T, Yoneda S, Kako T, et al. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther Toxicol. 1990;28:123-126.
39. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;133(9):745-746.
40. Bresolin N, Bet L, Binda A, et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology. 1988;38:892-899.
41. Nishikawa Y, Takahashi M, Yorfiji S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a phosphorus NMR study. Neurology. 1989;39:399-403.
42. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitoehondrial encephalomyopathies: short-term double-blind, crossover study. Eur Neurol. 1997;37:212-218.
43. Matthews PM, Ford B, Dandurand RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology. 1993;43:884-890.
44. Rotig A, Appelkvist EL, Geromel V, et al. CoQ10-responsive mitochondrial encephalomyopathy due to an inborn error of ubiquinone synthesis metabolism [abstract]. Am J Hum Genet. 1997;61(suppl 4):A358.
45. Lockwood K, Moesgaard S, Folkers K. (1994). Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Comm. 1994;199:1504-1508.
46. Folkers K, Brown R, Judy WV, et al. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Comm. 1993;192:241-245.
47. Lockwood K, Moesgaard S, Yamamoto T, et al. Progress on therapy of breast cancer with vitamin Q-10 and the regression of metastases. Biochem Biophys Res Comm 1995;212:172-177.
48. Shinozawa S, Gomita Y, Araki Y. Tissue concentration of doxorubicin (adriamycin) in mouse pretreated with alpha-tocopherol or coenzyme Q10. Acta Med Okayama 1991;45:195-200.
49. Shults CW, Beal MF, Fontaine D. et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 hi Parkinsonian patients. Neurology. 1998;50:793-795.
50. Krone CA, Elmer GW, Ely JTA, et al, Does gastrointestinal Candida albicans prevent ubiquinone absorption? Med Hypoth. 2001;57(5):570-572.
51. Baggio E, Gandini R. Plancher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Mol Aspects Med. 1994;15(suppl):S287-S294
52. Folkers K, Langsjoen P, Wiilis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA. 1990;87:8931-8934.
53. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelorschung. 1999;49:324-329.
54. Aberg F, Appelkvist EL, Broijersen A, et al. Gemfibrozil-induced decreased in serum ubiquinone and a- and g-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest. 1998;28:235-242.
55. Laaksonen R, Jokelainen K, Laakso J. et al. The effect of Simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996;77:851-854.
56. Palomäki A, Malminiemi K, Solakivi T. et al. Ubiquinone supplementation during lovastatin treatmem: effect on LDL oxidation ex vivo. J Lipid Res. 1998;39:1430-1437.
57. Heck AM, DeWitt BA. Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health-Syst Pharm. 2000;57:1221-1227.
58. Morton RA. Ubiquinones, plastoquinones and vitamins K. Biol Rev Camb Philos Soc. 1971;46:47-96.
59. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994;344:1372-1373.
60. Karila T, Laaksonen R, Jokelainen K, et al. The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers. Metabolism. 1996;45:844-847.
61. Feigin A, Kieburtz K, Como P, et al. An open-label trial of coenzyme Q10 (CoQ) in Huntington's disease (HD) [abstract]. Neurology. 1994;44(suppl 2):A397-A398.
62. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57(3):397-404.
63. Montaldo PL, Fenu MA, Tronci M, et al. Cardioprotection against high-dose 4′-epidoxo-rubicin by ICRF-187 and CoQ-10 [abstract 5A]. Anticancer Res. 1995;15:1760.
64. Lund EL, Quistorff B, Kristjansen PEG. Oral ubiquinone intake reduces the in vivo radiosensitivity of human small cell lung cancer [abstract]. Pro Am Assoc Cancer Res. 1997;38:248.